Roche Holding AG
F:RHO

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
F:RHO
Watchlist
Price: 247.6 EUR
Market Cap: 211.5B EUR

Gross Margin
Roche Holding AG

73.9%
Current
72%
Average
48.6%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
73.9%
=
Gross Profit
45.5B
/
Revenue
61.6B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
CH
Roche Holding AG
SIX:ROG
266.1B CHF
74%
US
Eli Lilly and Co
NYSE:LLY
1T USD
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
US
Johnson & Johnson
NYSE:JNJ
492.8B USD
68%
UK
AstraZeneca PLC
LSE:AZN
218.6B GBP
82%
CH
Novartis AG
SIX:NOVN
216.6B CHF
76%
US
Merck & Co Inc
NYSE:MRK
270.8B USD
79%
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
82%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
68%
US
Pfizer Inc
NYSE:PFE
144.6B USD
75%
FR
Sanofi SA
PAR:SAN
99.8B EUR
72%
No Stocks Found

Roche Holding AG
Glance View

Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.

RHO Intrinsic Value
335.67 EUR
Undervaluation 26%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
73.9%
=
Gross Profit
45.5B
/
Revenue
61.6B
What is the Gross Margin of Roche Holding AG?

Based on Roche Holding AG's most recent financial statements, the company has Gross Margin of 73.9%.

Back to Top